CGTLive’s Weekly Rewind – July 15, 2022
Review top news and interview highlights from the week ending July 15, 2022.
Welcome to CGTLive’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.
1. ATA188 Shows No Significant Improvements in MS, Study to Continue
There were not enough data at 6 months to predict expanded disability status scale (EDSS) improvements after treatment.
2. First Patient With Mesial Temporal Lobe Epilepsy Dosed With Neural Cell Therapy
Patient recruitment for the clinical trial is currently underway at epilepsy centers throughout the US.
3. First Patient With Familial Hypercholesteremia Dosed With Base-Editing Therapy
Verve Therapeutics is currently conducting a clinical trial in New Zealand and expects to be able to open trials in the UK and US later in 2022.
4. TCR T Cell Therapy for HBV-Related Liver Cancer Cleared for US Trial
SCG101 will be evaluated in trials across China, Singapore, and the US.
5. Legend Biotech Drops Lymphoma CAR T-Cell Therapy
Legend Biotech seeks to prioritize other product candidates in its pipeline.
Considerations for Administering Hemoglobinopathy Gene Therapies From a Pharmacist’s Perspective
April 20th 2024Alexis Kuhn, PharmD, BCOP, a pediatric oncology pharmacist at Mayo Clinic, discussed the incorporation of the recently FDA-approved gene therapies for SCD and TDT into the work of pharmacists.
